Pier Capital, LLC Maravai Lifesciences Holdings, Inc. Transaction History

Pier Capital, LLC

$714 Million
Q1 2024

A detailed history of Pier Capital, LLC transactions in Maravai Lifesciences Holdings, Inc. stock. As of the latest transaction made, Pier Capital, LLC holds 506,295 shares of MRVI stock, worth $3.54 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares

506,295

Previous 286,849 76.5%

Holding current value

$3.54 Million

Previous $1.88 Million 133.71%

% of portfolio

0.61%

Previous 0.27%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 02, 2024	BUY	$5.11 - $8.76 $1.12 Million - $1.92 Million	219,446 Added 76.5%	506,295 $4.39 Million
Q4 2023 Feb 15, 2024	SELL	$4.7 - $9.87 $17,455 - $36,657	-3,714 Reduced 1.28%	286,849 $1.88 Million
Q3 2023 Nov 14, 2023	SELL	$9.14 - $12.85 $50,151 - $70,507	-5,487 Reduced 1.85%	290,563 $2.91 Million
Q2 2023 Aug 14, 2023	SELL	$12.09 - $15.0 $64,052 - $79,470	-5,298 Reduced 1.76%	296,050 $3.68 Million
Q1 2023 May 10, 2023	BUY	$12.99 - $16.48 $379,217 - $481,100	29,193 Added 10.73%	301,348 $4.22 Million

Q4 2022 Feb 15, 2023	BUY	$12.5 - $24.78 $3.18 Million - $6.3 Million	254,314 Added 1425.45%	272,155 $3.89 Million
Q3 2022 Nov 15, 2022	SELL	$20.6 - $30.37 $283,971 - $418,650	-13,785 Reduced 43.59%	17,841 $455,000
Q2 2022 Aug 15, 2022	BUY	$26.05 - $37.48 $318,956 - $458,905	12,244 Added 63.17%	31,626 $898,000
Q1 2022 May 10, 2022	BUY	$24.46 - $40.92 $220,482 - $368,852	9,014 Added 86.94%	19,382 $684,000
Q4 2021 Feb 10, 2022	BUY	$35.0 - $45.94 $362,880 - $476,305	10,368 New	10,368 $434,000

Others Institutions Holding MRVI

# of Institutions

227

Shares Held

135M

Call Options Held

339K

Put Options Held

148K

View Full List

About MARAVAI LIFESCIENCES HOLDINGS, INC.

Ticker MRVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 131,540,000
Market Cap $919M
Description
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for dia...

More about MRVI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pier Capital, LLC with notifications on news.

Account